Provided by Tiger Fintech (Singapore) Pte. Ltd.

Candel Therapeutics, Inc.

4.90
+0.05001.03%
Volume:484.39K
Turnover:2.40M
Market Cap:268.99M
PE:-9.39
High:5.03
Open:4.94
Low:4.89
Close:4.85
52wk High:14.60
52wk Low:3.79
Shares:54.90M
Float Shares:45.48M
Volume Ratio:1.21
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5221
EPS(LYR):-1.7420
ROE:-55.18%
ROA:-33.39%
PB:2.98
PE(LYR):-2.81

Loading ...

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

GlobeNewswire
·
Yesterday

Candel Therapeutics Falls After Downgrade From BofA Securities

MT Newswires Live
·
Sep 04

BofA Securities Downgrades Candel Therapeutics to Neutral From Buy

MT Newswires Live
·
Sep 03

Candel Therapeutics Inc. Appoints Immunotherapy Pioneer Dr. Carl H. June to Research Advisory Board

Reuters
·
Sep 02

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.d., to Research Advisory Board

THOMSON REUTERS
·
Sep 02

Candel Therapeutics Inc. Set to Participate in Citi's 2025 Biopharma Back to School Conference in Boston

Reuters
·
Aug 28

BRIEF-Candel Therapeutics Extends Lease Term To Aug 31, 2029

Reuters
·
Aug 22

Candel Therapeutics Inc - on Aug 18, Extended Lease Term to Aug 31, 2029

THOMSON REUTERS
·
Aug 22

Candel Therapeutics Inc. Extends Lease Agreement for Needham Premises Until 2029

Reuters
·
Aug 22

Candel Therapeutics Inc. Unveils Corporate Presentation Highlighting Advances in Cancer Immunotherapy and Promising Clinical Trial Results

Reuters
·
Aug 15

Candel Therapeutics Inc Files for Mixed Shelf of Upto $300 Mln - SEC Filing

THOMSON REUTERS
·
Aug 14

Candel Therapeutics Reports Increased R&D Expenses in Q2 2025, Highlights FDA RMAT Designation for Prostate Cancer Treatment CAN-2409

Reuters
·
Aug 14

BRIEF-Candel Therapeutics Q2 Net Income USD -4.796 Million

Reuters
·
Aug 14

Candel Therapeutics' Chief Medical Officer William Garrett Nichols Reports Disposal of Common Shares

Reuters
·
Jul 31

Candel Therapeutics to Present at Canaccord Genuity 45th Annual Growth Conference

Reuters
·
Jul 30

Candel Therapeutics Secures EMA Orphan Designation for CAN-2409 in Pancreatic Cancer Treatment

Reuters
·
Jul 24

Candel Therapeutics Receives Ema Orphan Designation for Can-2409 for the Treatment of Pancreatic Cancer

THOMSON REUTERS
·
Jul 24

Candel Therapeutics Joins Multiple Russell Value Indexes in 2025 Reconstitution

Reuters
·
Jul 09

Candel Therapeutics Inc. Chief Medical Officer William Garrett Nichols Reports Disposal of Common Shares

Reuters
·
Jul 03

BRIEF-Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Reuters
·
Jun 24